ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics

Broad range RNA integrity and quality analysis kit for SCIEX capillary electrophoresis instruments launches at TIDES 2022

At TIDES 2022, SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches the RNA 9000 Purity & Integrity kit, for the BioPhase 8800 system and PA 800 Plus system.

As genomic medicine takes center stage and the demand for RNA-based therapeutics and vaccines grows, the integrity and quality of RNA species is increasingly important. Scientists have been faced with complex methods that have low resolution and poor transferability, as they work to accelerate therapeutic drug development and meet critical timelines. For intact mRNA analysis, scientists need validated, production-ready methods and instrument platforms that allow them to confidently distinguish desired therapeutic products from unwanted impurities.

This RNA 9000 Purity and Integrity kit is a purpose-built, high resolution analysis method for mRNA therapeutics. It was specifically designed to provide significantly higher resolution for a wide variety of therapeutically-relevant mRNA classes, from 50-9,000 bases.

“For scientists, this kit has the power and capability to transform the analysis of mRNA therapeutics and vaccines. Not only can it be used for final product quality control to assess quality and length post nanoparticle or viral vector encapsulation, but it can also be used during early-stage development immediately following IVT (in-vitro transcribe) to ensure the integrity and size of the mRNA payload is what the researchers are targeting. This kit is truly a unique solution with its analytical resolution,” said Jérémie Parot PhD, Research Scientist at SINTEF.

“The ability to help biopharmaceutical developers accelerate the development of RNA-based medicines and bridge the developability gap can bring more life-changing medicines to market,” said Susan Darling, Senior Director of CE and Biopharma at SCIEX. “Compatibility with both the BioPhase 8800 system and the PA 800 Plus system means scientists have the ability to run the assay in a 21cfr part 11b compliant way, across instruments, across sites, across the globe.”

With this kit, scientists could expect to:

  • Minimize time to market with exceptional reproducibility, experiment to experiment
  • Estimate a target therapeutic size
  • Experiment with minimal sample material and have the ability to detect low level impurities present in samples

To learn more about RNA 9000 Purity and Integrity kit, see here.

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com.

Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2022 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-14725-A.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.